Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tafenoquine

- PMLiVE

GSK, J&J say monthly injection keeps HIV controlled

The once every four-week treatment could free those from taking daily pills

- PMLiVE

GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

Partners to co-develop novel bifunctional fusion protein

- PMLiVE

Advair generics and acquisitions to hit GSK in 2019

Earnings to decline as company transforms

- PMLiVE

GSK’s Advair Diskus faces first generic in US

Analysts predict around $250m in sales for Wixela Inhub this year

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

- PMLiVE

GSK upbeat on its return to oncology market

Zejula signals comeback after four year hiatus

- PMLiVE

GSK and Pfizer to create combined consumer health titan

Spin-out will allow GSK to focus on prescription drugs and vaccines

- PMLiVE

GSK buys cancer firm Tesaro for $5.1bn

Acquisition re-establishes US commercial operations in oncology

- PMLiVE

GSK among businesses wooed as Brexit reckoning nears

Emma Walmsley to co-chair panel with supermarket CEO

- PMLiVE

Is GSK planning to exit the respiratory business?

Oncology head says opportunities diminishing despite firm's heritage

- PMLiVE

GSK’s says depot HIV injection works over three years

The injection could rival Gilead’s single-tablet therapy

- PMLiVE

GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

Company seeking to revive lacklustre marketing performance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links